Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) Return on Sales (2020 - 2025)

Lyell Immunopharma's Return on Sales history spans 5 years, with the latest figure at 2265.8% for Q3 2025.

  • For Q3 2025, Return on Sales fell 95580.0% year-over-year to 2265.8%; the TTM value through Sep 2025 reached 7989.83%, down 495992.0%, while the annual FY2024 figure was 5486.67%, 376702.0% down from the prior year.
  • Return on Sales for Q3 2025 was 2265.8% at Lyell Immunopharma, up from 5483.0% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.23% in Q4 2022 and bottomed at 21395.33% in Q3 2022.
  • The 5-year median for Return on Sales is 2097.24% (2023), against an average of 4480.9%.
  • The largest annual shift saw Return on Sales tumbled -2137759bps in 2022 before it surged 1929809bps in 2023.
  • A 5-year view of Return on Sales shows it stood at 16.73% in 2021, then surged by 99bps to 0.23% in 2022, then crashed by -1721920bps to 4032.62% in 2023, then crashed by -342bps to 17838.82% in 2024, then soared by 87bps to 2265.8% in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Return on Sales are 2265.8% (Q3 2025), 5483.0% (Q2 2025), and 7643.57% (Q1 2025).